The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...

BioTechnique broadens capabilities with end‑to‑end fill‑finish, advanced lyophilization development, and integrated multi‑temperature 3PL support. YORK, PA, UNITED STATES, March 5, 2026 /EINPresswire.

Fc receptors function as the essential bridge between the innate and adaptive immune systems. When antibodies bind to their ...

The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads to provide dual mechanisms of ...

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 ...

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care. In this summary of a panel discussion at the 2026 TTLC ...

In this GEN webinar, experts from ChemPartner, Philip Clarke, PhD, Hu Liu, PhD, and Greg Liang, MD, will provide an overview of some of the innovative platforms that are shaping the next-generation of ...

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

The 2 nd Next-Generation Conjugates Summit, designed to help you push the boundaries of bioconjugate drug development with next-generation payloads and formats to improve translation and show a ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...